International journal of obstetric anesthesia
-
The Gerard W. Ostheimer Lecture presented at the annual meeting of the Society of Obstetric Anesthesia and Perinatology (SOAP) is a one-year summary of the literature published in domains of interest to anesthesiologists who manage and care for obstetric patients. ⋯ Ostheimer Lecture presented at the 2019 SOAP meeting; the relevant literature from 2018 was summarized. The topics included in this review are maternal morbidity, antibiotic prophylaxis, anaphylaxis, the Lancet series on increasing cesarean delivery rates, the Robson Ten-Group Classification System, pelvic floor disorders, timing of delivery in nulliparous women, placenta accreta disorders, anesthesia for cesarean delivery, labor analgesia (including parturients with thrombocytopenia and tattoos, and epidural maintenance with the programmed intermittent epidural bolus technique), ultrasound use in obstetric anesthesia, and drugs in pregnancy.
-
Int J Obstet Anesth · May 2020
Antisepsis for neuraxial procedures in Irish obstetric units and its possible impact on patient safety. A survey of national practice and associated complications.
The Association of Anaesthetists' guidelines recommend 0.5% chlorhexidine gluconate for skin antisepsis before obstetric neuraxial procedures. In this national survey, we identified the practice of all 19 obstetric units in Ireland. A secondary aim was to investigate complications in units not following guidelines. ⋯ Twenty-one percent of obstetric anaesthesia units in Ireland, catering for one-third of the total deliveries, use the ChloraPrep™ swab-stick and consider it the safest form of application. Chlorhexidine gluconate has been implicated in devastating neurological injury, however there is no evidence that a less concentrated solution such as 0.5% is safer. We suggest a meticulous application technique should be considered more important for patient safety than the concentration of solution.
-
Int J Obstet Anesth · May 2020
Observational StudyHeterozygote carriers of mutations in the F11 gene, encoding Factor XI, have normal coagulation by thromboelastography during pregnancy.
Evidence to guide clinical decision-making in pregnant women who are usually asymptomatic, but identified as heterozygote carriers of F11 mutations, is lacking. We hypothesized that women identified on prenatal screening as heterozygous for a mutation in the F11 allele would have minimal evidence of an in vitro coagulation abnormality. ⋯ Despite lower FXI activity in the F11 mutation group, we found minimal differences in whole-blood measures of coagulation using thromboelastography. These findings support our hypothesis that a single copy of an F11 mutation does not produce significant evidence of an in vitro coagulation abnormality. Thromboelastography might be useful in determining the risk of neuraxial anesthesia in pregnant women, but additional work is required to establish the validity of this test.